Using epigenetics as an alternative treatment for bladder cancer: A literature review

Abstract

Background and objective:

Bladder cancer (BC) is the sixth most common cancer in the U.S., with risk factors such as smoking, older age, and male sex. The primary symptom is painless hematuria. Diagnosis is made through cystoscopy, though this method is invasive and expensive. The study investigates the potential of epigenetic modifications, such as DNA methylation, histone modification, and microRNAs (miRNAs), in diagnosing and treating BC.

Methods:

A literature review was conducted on epigenetic changes, specifically DNA methylation in genes such as CDH1 and RASSF1A, and their impact on bladder cancer development. Gene mutations (e.g. FGFR3, TP53) and their influence on cancer progression were also investigated. In addition, epigenetic therapies, such as DNA methylation inhibitors, were discussed as potential treatments for advanced BC.

Key findings and limitations:

Epigenetic changes, such as DNA methylation, contribute to the development of BC, and histone modifications affect gene expression. MiRNAs regulate cancer cell proliferation. Additionally, mutations in genes such as FGFR3 and TP53 are crucial for specific BC subtypes. Despite promising results, challenges such as treatment resistance and difficulties in patient selection for epigenetic therapies remain.

Conclusions and clinical implications:

Epigenetic changes could serve as biomarkers for BC and as therapeutic targets. Epigenetic therapies offer an alternative to traditional treatments, especially for advanced BC. Clinical trials are underway to address challenges such as treatment resistance and to refine patient selection for these therapies.

Patient summary:

Bladder cancer is common and is related to lifestyle and genetic factors. Advances in epigenetics could lead to more personalized and less invasive treatments, improving outcomes for patients with advanced BC.